Biogen (NASDAQ: BIIB) Chief Legal Officer Susan Alexander to depart

Rhea-AI Filing Summary

Biogen Inc. reported that its Chief Legal Officer, Susan H. Alexander, will leave the company effective at the end of May 2026. The company has started a search for her successor to lead its legal function. Other aspects of Biogen’s operations are not discussed in this report.

falseBIOGEN INC.0000875045DE225 BINNEY STREETCAMBRIDGE617679-2000NASDAQ00008750452026-03-112026-03-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 11, 2026

Biogen Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-19311	33-0112644
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

225 Binney Street, Cambridge, Massachusetts 02142

(Address of principal executive offices; Zip Code)

Registrant’s telephone number, including area code: (781) 464-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0005 par value	BIIB	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 11, 2026, Biogen Inc. (the “Company”) announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026. The Company has initiated a search to identify the Company’s next Chief Legal Officer.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Biogen Inc.
	By:	/s/ Wendell Taylor
		Wendell Taylor
		Secretary

Date: March 11, 2026

FAQ

What leadership change did Biogen (BIIB) disclose on March 11, 2026?

Biogen disclosed that Chief Legal Officer Susan H. Alexander will depart effective at the end of May 2026. The company has begun a search for a new Chief Legal Officer to oversee its legal affairs and regulatory responsibilities.

When is Biogen’s Chief Legal Officer Susan H. Alexander scheduled to leave?

Susan H. Alexander is scheduled to depart Biogen at the end of May 2026. This timing provides a transition window for the company as it conducts a search to identify and appoint the next Chief Legal Officer to lead its legal team.

What position is Biogen (BIIB) seeking to fill after this 8-K filing?

Biogen is seeking to fill the role of Chief Legal Officer following the planned departure of Susan H. Alexander. The company has initiated a formal search process to identify a successor to manage its legal, compliance, and governance responsibilities.

Does the Biogen (BIIB) update mention any change to its business operations?

The update focuses solely on the upcoming departure of Chief Legal Officer Susan H. Alexander. It does not describe any direct changes to Biogen’s products, financial results, or broader business operations beyond this executive leadership transition.

Who signed Biogen’s March 11, 2026 leadership change report?

The report was signed on behalf of Biogen Inc. by Wendell Taylor, who is identified as the company’s Secretary. His signature confirms that the disclosure about the Chief Legal Officer’s planned departure is an authorized corporate communication.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB